News
Adding cetuximab to afatinib provides no benefit in EGFR-mutant NSCLC
Survival outcomes were similar whether patients received afatinib alone or afatinib plus cetuximab.
News
No benefit with adjuvant sorafenib in intermediate-/high-risk RCC
Survival was similar with adjuvant sorafenib and placebo.
News
Baricitinib reduces adult atopic dermatitis severity in phase 3 study
In moderate to evere AD, baricitinib 4 mg on top of topical corticosteroids significantly reduced signs and symptoms.
News
Durable efficacy with MK-6482 in VHL-associated RCC
MK-6482 produced responses in patients with Von Hippel-Lindau disease-associated renal cell carcinoma and non-renal lesions.
News
Clinical factors and treatment tied to COVID-19 mortality in cancer patients
Analyses of CCC19 data revealed factors linked to mortality in patients with COVID-19 and cancer.
News
Apatinib plus gefitinib: Better PFS but more toxicity
Adding apatinib to gefitinib prolonged progression-free survival by 3.5 months.
News
Divergent findings with paclitaxel and nab-paclitaxel in TNBC
Atezolizumab may improve survival when it’s added to nab-paclitaxel but not paclitaxel, studies suggest.
News
No benefit with postoperative radiotherapy in stage IIIAN2 NSCLC
A randomized trial showed similar disease-free survival with and without postoperative radiotherapy.
News
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
News
COVID-19 impact: Less chemo, immune checkpoint inhibitors, and steroids
A survey finds the COVID-19 pandemic to have a significant impact on oncologists’ decision-making.